Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America
Resumen:
PURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS Weanalyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MMage40 yearsoryoungercomparedwith256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Ofthepatients age40 yearsoryounger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly.
| 2023 | |
|
PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
|
| Inglés | |
| Universidad de la República | |
| COLIBRI | |
| https://hdl.handle.net/20.500.12008/53300 | |
| Acceso abierto | |
| Licencia Creative Commons Atribución (CC - By 4.0) |
| _version_ | 1875692819519111168 |
|---|---|
| author | Martínez-Cordero, Humberto |
| author2 | Peña, Camila Schutz, Natalia Paola Bove, Virginia Villano, Fiorella Beltrán, Cecilia Donoso, Javiera López-Vidal, Hernán Roa Salinas, Macarena Alejandra Soto, Pablo Ochoa, Paola Duarte, Patricio Riva, Eloísa |
| author2_role | author author author author author author author author author author author author |
| author_facet | Martínez-Cordero, Humberto Peña, Camila Schutz, Natalia Paola Bove, Virginia Villano, Fiorella Beltrán, Cecilia Donoso, Javiera López-Vidal, Hernán Roa Salinas, Macarena Alejandra Soto, Pablo Ochoa, Paola Duarte, Patricio Riva, Eloísa |
| author_role | author |
| bitstream.checksum.fl_str_mv | 6429389a7df7277b72b7924fdc7d47a9 a0ebbeafb9d2ec7cbb19d7137ebc392c 5206de1c76e3f87e88ce235a55490bfa e7132498e7c1fe99f7096667baa99b25 2ea8c1add27c2f0a112a3059ed201fd3 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 MD5 MD5 MD5 |
| bitstream.url.fl_str_mv | http://localhost:8080/xmlui/bitstream/20.500.12008/53300/5/license.txt http://localhost:8080/xmlui/bitstream/20.500.12008/53300/2/license_url http://localhost:8080/xmlui/bitstream/20.500.12008/53300/3/license_text http://localhost:8080/xmlui/bitstream/20.500.12008/53300/4/license_rdf http://localhost:8080/xmlui/bitstream/20.500.12008/53300/1/Patients+Age+40+Years+and+Younger+With+Multiple+Myeloma.pdf |
| collection | COLIBRI |
| dc.contributor.filiacion.none.fl_str_mv | Martínez-Cordero Humberto, Instituto Nacional de Cancerología de Colombia (Colombia) Peña Camila, Hospital Del Salvador (Chile). Departamento de Hematología Schutz Natalia Paola, Hospital Italiano de Buenos Aires (Argentina) Bove Virginia, Asociación Española de Socorros Mutuos (Uruguay) Villano Fiorella, CASMU (Uruguay) Beltrán Cecilia, Hospital de Temuco (Chile) Donoso Javiera, Hospital Sótero del Río (Chile) López-Vidal Hernán, Hospital Barros Luco (Chile) Roa Salinas Macarena Alejandra, Hospital Del Salvador (Chile). Departamento de Hematología Soto Pablo, Hospital Dr. Eduardo Schütz Schroeder (Chile) Ochoa Paola, Instituto Alexander Fleming (Argentina) Duarte Patricio, CEMIC Hospital Universitario (Argentina) Riva Eloísa, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de Clínicas |
| dc.coverage.spatial.es.fl_str_mv | AMÉRICA LATINA |
| dc.creator.none.fl_str_mv | Martínez-Cordero, Humberto Peña, Camila Schutz, Natalia Paola Bove, Virginia Villano, Fiorella Beltrán, Cecilia Donoso, Javiera López-Vidal, Hernán Roa Salinas, Macarena Alejandra Soto, Pablo Ochoa, Paola Duarte, Patricio Riva, Eloísa |
| dc.date.accessioned.none.fl_str_mv | 2026-01-29T19:19:44Z |
| dc.date.available.none.fl_str_mv | 2026-01-29T19:19:44Z |
| dc.date.issued.none.fl_str_mv | 2023 |
| dc.description.abstract.none.fl_txt_mv | PURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS Weanalyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MMage40 yearsoryoungercomparedwith256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Ofthepatients age40 yearsoryounger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly. |
| dc.description.es.fl_txt_mv | Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodations, Expenses: Varifarma Cecilia Beltran Consulting or Advisory Role: Takeda Travel, Accommodations, Expenses: Janssen, Takeda Javiera Donoso Honoraria: Janssen Oncology Consulting or Advisory Role: Janssen Oncology Hern´ an L´ opez-Vidal Consulting or Advisory Role: Janssen Oncology, Pfizer, AbbVie Speakers’ Bureau: Janssen Oncology Travel, Accommodations, Expenses: Janssen Oncology, Pfizer Macarena Alejandra Roa Salinas Honoraria: AbbVie, AstraZeneca, Tecnofarma Consulting or Advisory Role: Janssen, Takeda, Tecnofarma Travel, Accommodations, Expenses: Roche Pablo Soto Travel, Accommodations, Expenses: Janssen Paola Ochoa Honoraria: Janssen, Sanofi Consulting or Advisory Role: Sanofi, Janssen Travel, Accommodations, Expenses: Janssen Patricio Duarte Consulting or Advisory Role: Janssen, Sanofi, Takeda Speakers’ Bureau: Sanofi Travel, Accommodations, Expenses: Sanofi Guillermina Remaggi Consulting or Advisory Role: Janssen-Cilag, Sanofi,Pfizer Speakers’ Bureau: Janssen Travel, Accommodations, Expenses: Janssen, Sanofi Claudia Shanley Honoraria: Takeda Consulting or Advisory Role: Sanofi, AbbVie, Janssen Travel, Accommodations, Expenses: Janssen Sergio Lopresti Honoraria: Janssen Oncology Dorotea Fantl Speakers’ Bureau: Janssen, Takeda, Sanofi, Amgen Research Funding: Janssen, Takeda, Helsinn Therapeutics, Sanofi, Roche Travel, Accommodations, Expenses: Janssen, Sanofi Guillermo Quintero Consulting or Advisory Role: Janssen Oncology, Pfizer, Takeda, Sanofi Travel, Accommodations, Expenses: AbbVie, Amgen, Janssen Oncology, Roche David Gomez-Almaguer Consulting or Advisory Role: Janssen, Takeda, Teva, BMS. Speakers’Bureau:Bristol MyersSquibb(Mexico),AbbVie,Novartis,Janssen, Amgen, Takeda Luis Antonio Salazar Honoraria: Janssen, AbbVie, AstraZeneca Consulting or Advisory Role: AstraZeneca, Janssen Travel, Accommodations, Expenses: Janssen Mar´ ıa Cynthia Fuentes-Lacouture Honoraria: Fresenius Kabi BioSimiliars Travel, Accommodations, Expenses: Janssen Mario Pereira Honoraria: Novartis, Amgen, Janssen, Pint Pharma Consulting or Advisory Role: Novartis Travel, Accommodations, Expenses: AbbVie. Jule Vasquez Honoraria: Janssen, Roche Consulting or Advisory Role: Janssen, AbbVie Research Funding: Roche (Inst) Travel, Accommodations, Expenses: Janssen, AbbVie Elo´ ısa Riva Honoraria: Sanofi, Janssen, AbbVie/Genentech Research Funding: Sebia (Inst) Travel, Accommodations, Expenses: Roemmers, Janssen, Sanof |
| dc.format.extent.es.fl_str_mv | 7 p. |
| dc.format.mimetype.es.fl_str_mv | application/pdf |
| dc.identifier.citation.es.fl_str_mv | Martínez-Cordero H, Peña C, Schutz N y otros. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America. JCO Global Oncology [en línea]. 2023;9. 7 p. |
| dc.identifier.doi.none.fl_str_mv | 10.1200/GO.23.00182 |
| dc.identifier.eissn.none.fl_str_mv | 2687-8941 |
| dc.identifier.uri.none.fl_str_mv | https://hdl.handle.net/20.500.12008/53300 |
| dc.language.iso.none.fl_str_mv | en eng |
| dc.publisher.es.fl_str_mv | American Society of Clinical Oncology |
| dc.relation.none.fl_str_mv | JCO Global Oncology. 2023;9 |
| dc.rights.license.none.fl_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| dc.rights.none.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.source.none.fl_str_mv | reponame:COLIBRI instname:Universidad de la República instacron:Universidad de la República |
| dc.subject.other.es.fl_str_mv | PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
| dc.title.none.fl_str_mv | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| dc.type.es.fl_str_mv | Artículo |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/article |
| dc.type.version.none.fl_str_mv | info:eu-repo/semantics/publishedVersion |
| description | Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodations, Expenses: Varifarma Cecilia Beltran Consulting or Advisory Role: Takeda Travel, Accommodations, Expenses: Janssen, Takeda Javiera Donoso Honoraria: Janssen Oncology Consulting or Advisory Role: Janssen Oncology Hern´ an L´ opez-Vidal Consulting or Advisory Role: Janssen Oncology, Pfizer, AbbVie Speakers’ Bureau: Janssen Oncology Travel, Accommodations, Expenses: Janssen Oncology, Pfizer Macarena Alejandra Roa Salinas Honoraria: AbbVie, AstraZeneca, Tecnofarma Consulting or Advisory Role: Janssen, Takeda, Tecnofarma Travel, Accommodations, Expenses: Roche Pablo Soto Travel, Accommodations, Expenses: Janssen Paola Ochoa Honoraria: Janssen, Sanofi Consulting or Advisory Role: Sanofi, Janssen Travel, Accommodations, Expenses: Janssen Patricio Duarte Consulting or Advisory Role: Janssen, Sanofi, Takeda Speakers’ Bureau: Sanofi Travel, Accommodations, Expenses: Sanofi Guillermina Remaggi Consulting or Advisory Role: Janssen-Cilag, Sanofi,Pfizer Speakers’ Bureau: Janssen Travel, Accommodations, Expenses: Janssen, Sanofi Claudia Shanley Honoraria: Takeda Consulting or Advisory Role: Sanofi, AbbVie, Janssen Travel, Accommodations, Expenses: Janssen Sergio Lopresti Honoraria: Janssen Oncology Dorotea Fantl Speakers’ Bureau: Janssen, Takeda, Sanofi, Amgen Research Funding: Janssen, Takeda, Helsinn Therapeutics, Sanofi, Roche Travel, Accommodations, Expenses: Janssen, Sanofi Guillermo Quintero Consulting or Advisory Role: Janssen Oncology, Pfizer, Takeda, Sanofi Travel, Accommodations, Expenses: AbbVie, Amgen, Janssen Oncology, Roche David Gomez-Almaguer Consulting or Advisory Role: Janssen, Takeda, Teva, BMS. Speakers’Bureau:Bristol MyersSquibb(Mexico),AbbVie,Novartis,Janssen, Amgen, Takeda Luis Antonio Salazar Honoraria: Janssen, AbbVie, AstraZeneca Consulting or Advisory Role: AstraZeneca, Janssen Travel, Accommodations, Expenses: Janssen Mar´ ıa Cynthia Fuentes-Lacouture Honoraria: Fresenius Kabi BioSimiliars Travel, Accommodations, Expenses: Janssen Mario Pereira Honoraria: Novartis, Amgen, Janssen, Pint Pharma Consulting or Advisory Role: Novartis Travel, Accommodations, Expenses: AbbVie. Jule Vasquez Honoraria: Janssen, Roche Consulting or Advisory Role: Janssen, AbbVie Research Funding: Roche (Inst) Travel, Accommodations, Expenses: Janssen, AbbVie Elo´ ısa Riva Honoraria: Sanofi, Janssen, AbbVie/Genentech Research Funding: Sebia (Inst) Travel, Accommodations, Expenses: Roemmers, Janssen, Sanof |
| eu_rights_str_mv | openAccess |
| format | article |
| id | COLIBRI_eceb6bc91f41361016f08bc980b1dc6f |
| identifier_str_mv | Martínez-Cordero H, Peña C, Schutz N y otros. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America. JCO Global Oncology [en línea]. 2023;9. 7 p. 10.1200/GO.23.00182 2687-8941 |
| instacron_str | Universidad de la República |
| institution | Universidad de la República |
| instname_str | Universidad de la República |
| language | eng |
| language_invalid_str_mv | en |
| network_acronym_str | COLIBRI |
| network_name_str | COLIBRI |
| oai_identifier_str | oai:colibri.udelar.edu.uy:20.500.12008/53300 |
| publishDate | 2023 |
| reponame_str | COLIBRI |
| repository.mail.fl_str_mv | karina.camps@seciu.edu.uy |
| repository.name.fl_str_mv | COLIBRI - Universidad de la República |
| repository_id_str | 4771 |
| rights_invalid_str_mv | Licencia Creative Commons Atribución (CC - By 4.0) |
| spelling | Martínez-Cordero Humberto, Instituto Nacional de Cancerología de Colombia (Colombia)Peña Camila, Hospital Del Salvador (Chile). Departamento de HematologíaSchutz Natalia Paola, Hospital Italiano de Buenos Aires (Argentina)Bove Virginia, Asociación Española de Socorros Mutuos (Uruguay)Villano Fiorella, CASMU (Uruguay)Beltrán Cecilia, Hospital de Temuco (Chile)Donoso Javiera, Hospital Sótero del Río (Chile)López-Vidal Hernán, Hospital Barros Luco (Chile)Roa Salinas Macarena Alejandra, Hospital Del Salvador (Chile). Departamento de HematologíaSoto Pablo, Hospital Dr. Eduardo Schütz Schroeder (Chile)Ochoa Paola, Instituto Alexander Fleming (Argentina)Duarte Patricio, CEMIC Hospital Universitario (Argentina)Riva Eloísa, Universidad de la República (Uruguay). Facultad de Medicina. Hospital de ClínicasAMÉRICA LATINA2026-01-29T19:19:44Z2026-01-29T19:19:44Z2023Martínez-Cordero H, Peña C, Schutz N y otros. Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America. JCO Global Oncology [en línea]. 2023;9. 7 p.https://hdl.handle.net/20.500.12008/5330010.1200/GO.23.001822687-8941Humberto Martinez-Cordero Honoraria: Janssen, Sanofi, Bristol Myers Squibb/Celgene, Takeda Consulting orAdvisoryRole: Janssen, Sanofi,Bristol MyersSquibb/Celgene, Takeda Travel, Accommodations, Expenses: Sanofi Camila Peña Honoraria: Janssen Consulting or Advisory Role: Janssen Travel, Accommodations, Expenses: Varifarma Cecilia Beltran Consulting or Advisory Role: Takeda Travel, Accommodations, Expenses: Janssen, Takeda Javiera Donoso Honoraria: Janssen Oncology Consulting or Advisory Role: Janssen Oncology Hern´ an L´ opez-Vidal Consulting or Advisory Role: Janssen Oncology, Pfizer, AbbVie Speakers’ Bureau: Janssen Oncology Travel, Accommodations, Expenses: Janssen Oncology, Pfizer Macarena Alejandra Roa Salinas Honoraria: AbbVie, AstraZeneca, Tecnofarma Consulting or Advisory Role: Janssen, Takeda, Tecnofarma Travel, Accommodations, Expenses: Roche Pablo Soto Travel, Accommodations, Expenses: Janssen Paola Ochoa Honoraria: Janssen, Sanofi Consulting or Advisory Role: Sanofi, Janssen Travel, Accommodations, Expenses: Janssen Patricio Duarte Consulting or Advisory Role: Janssen, Sanofi, Takeda Speakers’ Bureau: Sanofi Travel, Accommodations, Expenses: Sanofi Guillermina Remaggi Consulting or Advisory Role: Janssen-Cilag, Sanofi,Pfizer Speakers’ Bureau: Janssen Travel, Accommodations, Expenses: Janssen, Sanofi Claudia Shanley Honoraria: Takeda Consulting or Advisory Role: Sanofi, AbbVie, Janssen Travel, Accommodations, Expenses: Janssen Sergio Lopresti Honoraria: Janssen Oncology Dorotea Fantl Speakers’ Bureau: Janssen, Takeda, Sanofi, Amgen Research Funding: Janssen, Takeda, Helsinn Therapeutics, Sanofi, Roche Travel, Accommodations, Expenses: Janssen, Sanofi Guillermo Quintero Consulting or Advisory Role: Janssen Oncology, Pfizer, Takeda, Sanofi Travel, Accommodations, Expenses: AbbVie, Amgen, Janssen Oncology, Roche David Gomez-Almaguer Consulting or Advisory Role: Janssen, Takeda, Teva, BMS. Speakers’Bureau:Bristol MyersSquibb(Mexico),AbbVie,Novartis,Janssen, Amgen, Takeda Luis Antonio Salazar Honoraria: Janssen, AbbVie, AstraZeneca Consulting or Advisory Role: AstraZeneca, Janssen Travel, Accommodations, Expenses: Janssen Mar´ ıa Cynthia Fuentes-Lacouture Honoraria: Fresenius Kabi BioSimiliars Travel, Accommodations, Expenses: Janssen Mario Pereira Honoraria: Novartis, Amgen, Janssen, Pint Pharma Consulting or Advisory Role: Novartis Travel, Accommodations, Expenses: AbbVie. Jule Vasquez Honoraria: Janssen, Roche Consulting or Advisory Role: Janssen, AbbVie Research Funding: Roche (Inst) Travel, Accommodations, Expenses: Janssen, AbbVie Elo´ ısa Riva Honoraria: Sanofi, Janssen, AbbVie/Genentech Research Funding: Sebia (Inst) Travel, Accommodations, Expenses: Roemmers, Janssen, SanofPURPOSE Multiple myeloma (MM) is a highly heterogeneous, incurable disease most frequently diagnosed in the elderly. Therefore, data on clinical characteristics and outcomes in the very young population are scarce. PATIENTS AND METHODS Weanalyzed clinical characteristics, response to treatment, and survival in 103 patients with newly diagnosed MMage40 yearsoryoungercomparedwith256 patients age 41-50 years and 957 patients age 51 years or older. RESULTS There were no statistical differences in sex, isotype, International Scoring System, renal involvement, hypercalcemia, anemia, dialysis, bony lesions, extramedullary disease, and lactate dehydrogenase (LDH). The most used regimen in young patients was cyclophosphamide, bortezomib, dexamethasone, followed by cyclophosphamide, thalidomide, dexamethasone and bortezomib, thalidomide, dexamethasone. Ofthepatients age40 yearsoryounger, only 53% received autologous stem-cell transplant (ASCT) and 71.1% received maintenance. There were no differences in overall survival (OS) in the three patient cohorts. In the multivariate analysis, only high LDH, high cytogenetic risk, and ASCT were statistically associated with survival. CONCLUSION In conclusion, younger patients with MM in Latin America have similar clinical characteristics, responses, and OS compared with the elderly.Submitted by Almiñana María Cecilia (marialminana@gmail.com) on 2026-01-28T15:12:47Z No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) Patients Age 40 Years and Younger With Multiple Myeloma.pdf: 3434851 bytes, checksum: 2ea8c1add27c2f0a112a3059ed201fd3 (MD5)Approved for entry into archive by Almiñana María Cecilia (marialminana@gmail.com) on 2026-01-29T11:12:24Z (GMT) No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) Patients Age 40 Years and Younger With Multiple Myeloma.pdf: 3434851 bytes, checksum: 2ea8c1add27c2f0a112a3059ed201fd3 (MD5)Made available in DSpace by Camps Karina (karina.camps@seciu.edu.uy) on 2026-01-29T19:19:44Z (GMT). No. of bitstreams: 2 license_rdf: 25630 bytes, checksum: e7132498e7c1fe99f7096667baa99b25 (MD5) Patients Age 40 Years and Younger With Multiple Myeloma.pdf: 3434851 bytes, checksum: 2ea8c1add27c2f0a112a3059ed201fd3 (MD5) Previous issue date: 20237 p.application/pdfenengAmerican Society of Clinical OncologyJCO Global Oncology. 2023;9Las obras depositadas en el Repositorio se rigen por la Ordenanza de los Derechos de la Propiedad Intelectual de la Universidad de la República.(Res. Nº 91 de C.D.C. de 8/III/1994 – D.O. 7/IV/1994) y por la Ordenanza del Repositorio Abierto de la Universidad de la República (Res. Nº 16 de C.D.C. de 07/10/2014)info:eu-repo/semantics/openAccessLicencia Creative Commons Atribución (CC - By 4.0)PERSONA DE MEDIANA EDADPROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICABORTEZOMIBCICLOFOSFAMIDADEXAMETASONAMIELOMA MÚLTIPLEPRONÓSTICOTALIDOMIDARESULTADO DEL TRATAMIENTOUSOS TERAPÉUTICOSQUIMIOTERAPIAEPIDEMIOLOGÍAPatients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin AmericaArtículoinfo:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionreponame:COLIBRIinstname:Universidad de la Repúblicainstacron:Universidad de la RepúblicaMartínez-Cordero, HumbertoPeña, CamilaSchutz, Natalia PaolaBove, VirginiaVillano, FiorellaBeltrán, CeciliaDonoso, JavieraLópez-Vidal, HernánRoa Salinas, Macarena AlejandraSoto, PabloOchoa, PaolaDuarte, PatricioRiva, EloísaLICENSElicense.txtlicense.txttext/plain; charset=utf-84267http://localhost:8080/xmlui/bitstream/20.500.12008/53300/5/license.txt6429389a7df7277b72b7924fdc7d47a9MD55CC-LICENSElicense_urllicense_urltext/plain; charset=utf-844http://localhost:8080/xmlui/bitstream/20.500.12008/53300/2/license_urla0ebbeafb9d2ec7cbb19d7137ebc392cMD52license_textlicense_texttext/html; charset=utf-835433http://localhost:8080/xmlui/bitstream/20.500.12008/53300/3/license_text5206de1c76e3f87e88ce235a55490bfaMD53license_rdflicense_rdfapplication/rdf+xml; charset=utf-825630http://localhost:8080/xmlui/bitstream/20.500.12008/53300/4/license_rdfe7132498e7c1fe99f7096667baa99b25MD54ORIGINALPatients Age 40 Years and Younger With Multiple Myeloma.pdfPatients Age 40 Years and Younger With Multiple Myeloma.pdfapplication/pdf3434851http://localhost:8080/xmlui/bitstream/20.500.12008/53300/1/Patients+Age+40+Years+and+Younger+With+Multiple+Myeloma.pdf2ea8c1add27c2f0a112a3059ed201fd3MD5120.500.12008/533002026-01-29 16:19:44.651oai:colibri.udelar.edu.uy:20.500.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Institucionalhttps://www.colibri.udelar.edu.uyUniversidadhttps://udelar.edu.uy/https://www.colibri.udelar.edu.uy/oai/requestkarina.camps@seciu.edu.uyUruguayopendoar:47712026-01-29T19:19:44COLIBRI - Universidad de la Repúblicafalse |
| spellingShingle | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America Martínez-Cordero, Humberto PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
| status_str | publishedVersion |
| title | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_full | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_fullStr | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_full_unstemmed | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_short | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| title_sort | Patients Age 40 Years and Younger With Multiple Myeloma Have the Same Prognosis as Older Patients: An Analysis of Real-World Patients’ Evidence From Latin America |
| topic | PERSONA DE MEDIANA EDAD PROTOCOLOS DE QUIMIOTERAPIA COMBINADA ANTINEOPLÁSICA BORTEZOMIB CICLOFOSFAMIDA DEXAMETASONA MIELOMA MÚLTIPLE PRONÓSTICO TALIDOMIDA RESULTADO DEL TRATAMIENTO USOS TERAPÉUTICOS QUIMIOTERAPIA EPIDEMIOLOGÍA |
| url | https://hdl.handle.net/20.500.12008/53300 |
